Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

DNA methyltransferase inhibitors induce a BRCAness phenotype that sensitizes NSCLC to PARP inhibitor and ionizing radiation.

Abbotts R, Topper MJ, Biondi C, Fontaine D, Goswami R, Stojanovic L, Choi EY, McLaughlin L, Kogan AA, Xia L, Lapidus R, Mahmood J, Baylin SB, Rassool FV.

Proc Natl Acad Sci U S A. 2019 Nov 5;116(45):22609-22618. doi: 10.1073/pnas.1903765116. Epub 2019 Oct 7.

PMID:
31591209
2.

Partnering with PARP inhibitors in acute myeloid leukemia with FLT3-ITD.

Dellomo AJ, Baer MR, Rassool FV.

Cancer Lett. 2019 Jul 10;454:171-178. doi: 10.1016/j.canlet.2019.03.048. Epub 2019 Apr 4.

PMID:
30953707
3.

Exploiting epigenetically mediated changes: Acute myeloid leukemia, leukemia stem cells and the bone marrow microenvironment.

Kogan AA, Lapidus RG, Baer MR, Rassool FV.

Adv Cancer Res. 2019;141:213-253. doi: 10.1016/bs.acr.2018.12.005. Epub 2019 Jan 21.

PMID:
30691684
4.

Retraction: Aromatase Inhibitor-mediated Downregulation of INrf2 (Keap1) Leads to Increased Nrf2 and Resistance in Breast Cancer.

Khatri R, Shah P, Guha R, Rassool FV, Tomkinson AE, Brodie A, Jaiswal AK.

Mol Cancer Ther. 2018 Nov;17(11):2491. doi: 10.1158/1535-7163.MCT-17-0310. No abstract available.

5.

An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.

Pulliam N, Fang F, Ozes AR, Tang J, Adewuyi A, Keer H, Lyons J, Baylin SB, Matei D, Nakshatri H, Rassool FV, Miller KD, Nephew KP.

Clin Cancer Res. 2018 Jul 1;24(13):3163-3175. doi: 10.1158/1078-0432.CCR-18-0204. Epub 2018 Apr 3.

6.

CHD4 Has Oncogenic Functions in Initiating and Maintaining Epigenetic Suppression of Multiple Tumor Suppressor Genes.

Xia L, Huang W, Bellani M, Seidman MM, Wu K, Fan D, Nie Y, Cai Y, Zhang YW, Yu LR, Li H, Zahnow CA, Xie W, Chiu Yen RW, Rassool FV, Baylin SB.

Cancer Cell. 2017 May 8;31(5):653-668.e7. doi: 10.1016/j.ccell.2017.04.005.

7.

Enhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents - A Potential Therapy for Cancer.

Muvarak NE, Chowdhury K, Xia L, Robert C, Choi EY, Cai Y, Bellani M, Zou Y, Singh ZN, Duong VH, Rutherford T, Nagaria P, Bentzen SM, Seidman MM, Baer MR, Lapidus RG, Baylin SB, Rassool FV.

Cancer Cell. 2016 Oct 10;30(4):637-650. doi: 10.1016/j.ccell.2016.09.002.

8.

High-Fidelity Reprogrammed Human IPSCs Have a High Efficacy of DNA Repair and Resemble hESCs in Their MYC Transcriptional Signature.

Nagaria PK, Robert C, Park TS, Huo JS, Zambidis ET, Rassool FV.

Stem Cells Int. 2016;2016:3826249. doi: 10.1155/2016/3826249. Epub 2016 Sep 1.

9.

Pim kinase inhibition sensitizes FLT3-ITD acute myeloid leukemia cells to topoisomerase 2 inhibitors through increased DNA damage and oxidative stress.

Doshi KA, Trotta R, Natarajan K, Rassool FV, Tron AE, Huszar D, Perrotti D, Baer MR.

Oncotarget. 2016 Jul 26;7(30):48280-48295. doi: 10.18632/oncotarget.10209.

10.

Histone deacetylase inhibitors decrease NHEJ both by acetylation of repair factors and trapping of PARP1 at DNA double-strand breaks in chromatin.

Robert C, Nagaria PK, Pawar N, Adewuyi A, Gojo I, Meyers DJ, Cole PA, Rassool FV.

Leuk Res. 2016 Jun;45:14-23. doi: 10.1016/j.leukres.2016.03.007. Epub 2016 Mar 30.

11.

Hydroxylated Dimeric Naphthoquinones Increase the Generation of Reactive Oxygen Species, Induce Apoptosis of Acute Myeloid Leukemia Cells and Are Not Substrates of the Multidrug Resistance Proteins ABCB1 and ABCG2.

Lapidus RG, Carter-Cooper BA, Sadowska M, Choi EY, Wonodi O, Muvarak N, Natarajan K, Pidugu LS, Jaiswal A, Toth EA, Rassool FV, Etemadi A, Sausville EA, Baer MR, Emadi A.

Pharmaceuticals (Basel). 2016 Jan 19;9(1). pii: E4. doi: 10.3390/ph9010004.

12.

Aromatase Inhibitor-Mediated Downregulation of INrf2 (Keap1) Leads to Increased Nrf2 and Resistance in Breast Cancer.

Khatri R, Shah P, Guha R, Rassool FV, Tomkinson AE, Brodie A, Jaiswal AK.

Mol Cancer Ther. 2015 Jul;14(7):1728-37. doi: 10.1158/1535-7163.MCT-14-0672. Epub 2015 May 14. Retraction in: Mol Cancer Ther. 2018 Nov;17(11):2491.

13.

c-MYC Generates Repair Errors via Increased Transcription of Alternative-NHEJ Factors, LIG3 and PARP1, in Tyrosine Kinase-Activated Leukemias.

Muvarak N, Kelley S, Robert C, Baer MR, Perrotti D, Gambacorti-Passerini C, Civin C, Scheibner K, Rassool FV.

Mol Cancer Res. 2015 Apr;13(4):699-712. doi: 10.1158/1541-7786.MCR-14-0422. Epub 2015 Mar 31.

14.

High frequency of rare structural chromosome abnormalities at relapse of cytogenetically normal acute myeloid leukemia with FLT3 internal tandem duplication.

Gourdin TS, Zou Y, Ning Y, Emadi A, Duong VH, Tidwell ML, Chen C, Rassool FV, Baer MR.

Cancer Genet. 2014 Oct-Dec;207(10-12):467-73. doi: 10.1016/j.cancergen.2014.09.001. Epub 2014 Sep 16.

PMID:
25441683
15.

Oxidative stress leads to increased mutation frequency in a murine model of myelodysplastic syndrome.

Chung YJ, Robert C, Gough SM, Rassool FV, Aplan PD.

Leuk Res. 2014 Jan;38(1):95-102. doi: 10.1016/j.leukres.2013.07.008. Epub 2013 Aug 16.

16.

Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile.

Cramer-Morales K, Nieborowska-Skorska M, Scheibner K, Padget M, Irvine DA, Sliwinski T, Haas K, Lee J, Geng H, Roy D, Slupianek A, Rassool FV, Wasik MA, Childers W, Copland M, Müschen M, Civin CI, Skorski T.

Blood. 2013 Aug 15;122(7):1293-304. doi: 10.1182/blood-2013-05-501072. Epub 2013 Jul 8.

17.

HDAC inhibitors: roles of DNA damage and repair.

Robert C, Rassool FV.

Adv Cancer Res. 2012;116:87-129. doi: 10.1016/B978-0-12-394387-3.00003-3. Review.

PMID:
23088869
18.

DNA double-strand break response in stem cells: mechanisms to maintain genomic integrity.

Nagaria P, Robert C, Rassool FV.

Biochim Biophys Acta. 2013 Feb;1830(2):2345-53. doi: 10.1016/j.bbagen.2012.09.001. Epub 2012 Sep 17. Review.

PMID:
22995214
19.

Targeting abnormal DNA double-strand break repair in tyrosine kinase inhibitor-resistant chronic myeloid leukemias.

Tobin LA, Robert C, Rapoport AP, Gojo I, Baer MR, Tomkinson AE, Rassool FV.

Oncogene. 2013 Apr 4;32(14):1784-93. doi: 10.1038/onc.2012.203. Epub 2012 May 28.

20.

Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells.

Tsai HC, Li H, Van Neste L, Cai Y, Robert C, Rassool FV, Shin JJ, Harbom KM, Beaty R, Pappou E, Harris J, Yen RW, Ahuja N, Brock MV, Stearns V, Feller-Kopman D, Yarmus LB, Lin YC, Welm AL, Issa JP, Minn I, Matsui W, Jang YY, Sharkis SJ, Baylin SB, Zahnow CA.

Cancer Cell. 2012 Mar 20;21(3):430-46. doi: 10.1016/j.ccr.2011.12.029.

21.

Genomic instability in chronic myeloid leukemia: targets for therapy?

Muvarak N, Nagaria P, Rassool FV.

Curr Hematol Malig Rep. 2012 Jun;7(2):94-102. doi: 10.1007/s11899-012-0119-0.

PMID:
22427031
22.

Targeting abnormal DNA repair in therapy-resistant breast cancers.

Tobin LA, Robert C, Nagaria P, Chumsri S, Twaddell W, Ioffe OB, Greco GE, Brodie AH, Tomkinson AE, Rassool FV.

Mol Cancer Res. 2012 Jan;10(1):96-107. doi: 10.1158/1541-7786.MCR-11-0255. Epub 2011 Nov 23.

23.

Human induced pluripotent cells resemble embryonic stem cells demonstrating enhanced levels of DNA repair and efficacy of nonhomologous end-joining.

Fan J, Robert C, Jang YY, Liu H, Sharkis S, Baylin SB, Rassool FV.

Mutat Res. 2011 Aug 1;713(1-2):8-17. doi: 10.1016/j.mrfmmm.2011.05.018. Epub 2011 Jun 28.

24.

KLFs and ATRA-induced differentiation: new pathways for exploitation.

Karp JE, Rassool FV.

Leuk Res. 2011 Jul;35(7):846-7. doi: 10.1016/j.leukres.2011.04.002. Epub 2011 May 4. No abstract available.

PMID:
21543117
25.

Defective nonhomologous end joining blocks B-cell development in FLT3/ITD mice.

Li L, Zhang L, Fan J, Greenberg K, Desiderio S, Rassool FV, Small D.

Blood. 2011 Mar 17;117(11):3131-9. doi: 10.1182/blood-2010-05-286070. Epub 2011 Jan 12.

26.

Cancer-related epigenome changes associated with reprogramming to induced pluripotent stem cells.

Ohm JE, Mali P, Van Neste L, Berman DM, Liang L, Pandiyan K, Briggs KJ, Zhang W, Argani P, Simons B, Yu W, Matsui W, Van Criekinge W, Rassool FV, Zambidis E, Schuebel KE, Cope L, Yen J, Mohammad HP, Cheng L, Baylin SB.

Cancer Res. 2010 Oct 1;70(19):7662-73. doi: 10.1158/0008-5472.CAN-10-1361. Epub 2010 Sep 14.

27.

Targeting abnormal DNA double strand break repair in cancer.

Rassool FV, Tomkinson AE.

Cell Mol Life Sci. 2010 Nov;67(21):3699-710. doi: 10.1007/s00018-010-0493-5. Epub 2010 Aug 10. Review.

28.

Regulation of differentiation by a PHD domain in the NUP98-PHF23 fusion protein.

Reader JC, Leng Q, Rassool FV, Ning Y.

Leuk Res. 2010 Aug;34(8):1094-7. doi: 10.1016/j.leukres.2010.02.015. Epub 2010 Mar 12.

PMID:
20219246
29.

Up-regulation of WRN and DNA ligase IIIalpha in chronic myeloid leukemia: consequences for the repair of DNA double-strand breaks.

Sallmyr A, Tomkinson AE, Rassool FV.

Blood. 2008 Aug 15;112(4):1413-23. doi: 10.1182/blood-2007-07-104257. Epub 2008 Jun 4.

30.

Genomic instability in myeloid malignancies: increased reactive oxygen species (ROS), DNA double strand breaks (DSBs) and error-prone repair.

Sallmyr A, Fan J, Rassool FV.

Cancer Lett. 2008 Oct 18;270(1):1-9. doi: 10.1016/j.canlet.2008.03.036. Epub 2008 May 7. Review.

PMID:
18467025
31.

Reactive oxygen species, DNA damage, and error-prone repair: a model for genomic instability with progression in myeloid leukemia?

Rassool FV, Gaymes TJ, Omidvar N, Brady N, Beurlet S, Pla M, Reboul M, Lea N, Chomienne C, Thomas NS, Mufti GJ, Padua RA.

Cancer Res. 2007 Sep 15;67(18):8762-71.

32.

Histone deacetylase inhibitors (HDI) cause DNA damage in leukemia cells: a mechanism for leukemia-specific HDI-dependent apoptosis?

Gaymes TJ, Padua RA, Pla M, Orr S, Omidvar N, Chomienne C, Mufti GJ, Rassool FV.

Mol Cancer Res. 2006 Aug;4(8):563-73.

33.
34.

Differentially expressed genes in adult familial myelodysplastic syndromes.

Pradhan A, Mijovic A, Mills K, Cumber P, Westwood N, Mufti GJ, Rassool FV.

Leukemia. 2004 Mar;18(3):449-59.

PMID:
14737073
35.

Constitutive DNA damage is linked to DNA replication abnormalities in Bloom's syndrome cells.

Rassool FV, North PS, Mufti GJ, Hickson ID.

Oncogene. 2003 Nov 27;22(54):8749-57.

PMID:
14647470
36.
37.
38.

P15INK4B is not mutated in adult familial myelodysplastic syndromes.

Cameron E, Mijovic A, Herman JG, Baylin SB, Pradhan A, Mufti GJ, Rassool FV.

Br J Haematol. 2002 Oct;119(1):277-9. No abstract available.

PMID:
12358941
40.

Increased error-prone non homologous DNA end-joining--a proposed mechanism of chromosomal instability in Bloom's syndrome.

Gaymes TJ, North PS, Brady N, Hickson ID, Mufti GJ, Rassool FV.

Oncogene. 2002 Apr 11;21(16):2525-33.

41.

Aberrant FHIT mRNA transcripts are present in malignant and normal haematopoiesis, but absence of FHIT protein is restricted to leukaemia.

Peters UR, Hasse U, Oppliger E, Tschan M, Ong ST, Rassool FV, Borisch B, Tobler A, Fey MF.

Oncogene. 1999 Jan 7;18(1):79-85.

42.

Replication of a common fragile site, FRA3B, occurs late in S phase and is delayed further upon induction: implications for the mechanism of fragile site induction.

Le Beau MM, Rassool FV, Neilly ME, Espinosa R 3rd, Glover TW, Smith DI, McKeithan TW.

Hum Mol Genet. 1998 Apr;7(4):755-61.

PMID:
9499431
43.

An FHIT tumor suppressor gene?

Le Beau MM, Drabkin H, Glover TW, Gemmill R, Rassool FV, McKeithan TW, Smith DI.

Genes Chromosomes Cancer. 1998 Apr;21(4):281-9. Review.

PMID:
9559339
44.
45.

FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer-related FHIT cDNA splicing aberrations.

Fong KM, Biesterveld EJ, Virmani A, Wistuba I, Sekido Y, Bader SA, Ahmadian M, Ong ST, Rassool FV, Zimmerman PV, Giaccone G, Gazdar AF, Minna JD.

Cancer Res. 1997 Jun 1;57(11):2256-67.

46.

Direct cloning of DNA sequences from the common fragile site region at chromosome band 3p14.2.

Rassool FV, Le Beau MM, Shen ML, Neilly ME, Espinosa R 3rd, Ong ST, Boldog F, Drabkin H, McCarroll R, McKeithan TW.

Genomics. 1996 Jul 1;35(1):109-17.

PMID:
8661111
47.

Localization of the Chinese hamster MHC locus to chromosome 1q17-->q18 by fluorescence in situ hybridization.

Rassool FV, Neilly ME, McGuire KL, McKeithan TW, Le Beau MM.

Cytogenet Cell Genet. 1995;71(1):62-3.

PMID:
7606930
48.

Increased genetic instability of the common fragile site at 3p14 after integration of exogenous DNA.

Rassool FV, Le Beau MM, Neilly ME, van Melle E, Espinosa R 3rd, McKeithan TW.

Am J Hum Genet. 1992 Jun;50(6):1243-51.

49.

Preferential integration of marker DNA into the chromosomal fragile site at 3p14: an approach to cloning fragile sites.

Rassool FV, McKeithan TW, Neilly ME, van Melle E, Espinosa R 3rd, Le Beau MM.

Proc Natl Acad Sci U S A. 1991 Aug 1;88(15):6657-61.

50.

The calcitonin-like sequence of the beta CGRP gene.

Alevizaki M, Shiraishi A, Rassool FV, Ferrier GJ, MacIntyre I, Legon S.

FEBS Lett. 1986 Sep 29;206(1):47-52.

Supplemental Content

Loading ...
Support Center